Saturday, August 12, 2023 10:44:57 AM
Recent CMMB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 11:00:40 AM
- Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:05:07 AM
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 03/25/2024 11:06:46 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 12:00:10 PM
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/07/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Biotech Shares Massively Bid Up Before Opening Bell • AllPennyStocks.com • 02/20/2024 02:20:00 PM
- Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 02/14/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/05/2024 12:00:00 PM
- Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:00:16 PM
- Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis • PR Newswire (US) • 11/16/2023 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/15/2023 09:35:45 PM
- Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis • PR Newswire (US) • 11/15/2023 12:00:00 PM
- Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 • PR Newswire (US) • 11/13/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:00:12 PM
- Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/09/2023 01:00:00 PM
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM